Azilect + Antidepressant Chart Review

Inclusion criteria

• Male or female patients with a diagnosis of PD
• Rasagiline treatment as mono- or adjunct therapy for PD with concomitant antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time during the specified review period, OR Rasagiline treatment as mono- or adjunct therapy for PD without concomitant antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time during the specified review period. OR Antidepressant therapy (SSRIs, SNRIs, St. John's wort and/or TCAs) and any other dopaminergic anti-PD treatment besides rasagiline or selegiline at any time during the specified review period
• Willing to consent to review of office chart and to review of records of ER visits and/or hospitalizations corresponding to the review window, if required
• Patients previously participating in a rasagiline clinical trial (and their follow-up protocols) are eligible, provided that they did not receive antidepressant therapy during trial participation.
• In addition to the above criteria, each group has specific inclusion criteria stated below:

• Group R+AD: Enrollment in this group requires that patients must have taken rasagiline and an antidepressant (SSRIs, SNRIs, St. John's wort and/or TCAs, regardless of indication) within 14 days of each other (or five weeks, if fluoxetine preceded rasagiline).
• Group R: Enrollment in this group requires patients must have at least 2 months of rasagiline use.
• Group AD: Patients must be taking an approved dopaminergic medication for PD. Enrollment in this group requires that patients must have at least 2 months of treatment with an antidepressant medication.

Exclusion criteria

• Use of rasagiline for any indication other than PD
• Patients taking a monoamine oxidase inhibitor (MAOI) antidepressant and/or selegiline
• Inability or unwillingness to request records of ER visits and/or hospitalizations corresponding to the review period.